Management strategies: Management of papillary and follicular cancer o
f the thyroid Varies somewhat between centers because of the generally
good prognosis and the absence of well-controlled therapeutic trials.
The internationally recognized TNM system is widely used to modulate
treatment and follow-up to the individual situation. Primary treatment
: Surgery is indicated in well-differentiated thyroid cancer Total thy
roidectomy is required for clinically patent tumors (greater than or e
qual to 1 cm) and small tumors (greater than or equal to 1 cm) recogni
zed prior to surgery. For small tumors found at histology examination,
reoperation is discussed in terms of prognosis. Post-operative 131-io
dine is indicated when surgical resection is incomplete or in case of
unfavorable prognosis. External radiotherapy is currently reserved for
exceptional cases with unremoved tumoral tissue unresponsive to 131-i
odine. Follow-up: All operated patients are given L-thyroxine to achie
ve euthyroidism and low TSH levels (< 0.1 mu U/ml). Early detection of
relapse is based on combined thyroglobulin assay and whole body 131-i
odine scintigraphy. Both are performed during the first year of follow
-up after a period of thyroid hormone withdrawal. Human recombinant TS
H will soon be available allowing selection of patients with a detecta
ble thyroglobulin level after stimulation; these patients should have
a 131-iodine scintigram. If thyroglobulin remains undetectable during
L-thyroxine treatment, an annual dosage is indicated and other exams a
re unwarranted. Relapse: Surgery is indicated in case of small areas o
f active recurrent tumoral tissue in a cervical location. If a high-se
nsitivity scintigram does not show iodine uptake, the surgical procedu
re is completed by radiotherapy or possibly chemotherapy with doxorubi
cin. Small recurrent tumors in other areas respond to 131-iodine (3.7
GBq). Surgery, 131-iodine and radiotherapy are usually indicated for l
arge ectopic recurrences. Chemotherapy is ineffective. Current protoco
ls: Standard primary therapy generally provides cure and most patients
are followed by annual thyroglobulin and TSH assays. Other exploratio
ns beginning with a whole-body 131-scintigram may be indicated in sele
cted patients.